Open access
Open access
Powered by Google Translator Translator

Nephrology

#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo

18 Nov, 2020 | 09:08h | UTC

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk – SCORED – American College of Cardiology

 


KDIGO Guideline Synopsis: Diabetes management in chronic kidney disease. Use of ACE inhibitors or ARBs, glycemic monitoring and targets, and choice of antihyperglycemic drugs are covered

11 Nov, 2020 | 09:09h | UTC

Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline – Annals of Internal Medicine

Original guideline: Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

 


Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more

5 Nov, 2020 | 08:58h | UTC

Clinical Management of Hyperkalemia – Mayo Clinic Proceedings

 


The value of urinary sodium assessment in acute heart failure

3 Nov, 2020 | 03:02h | UTC

The value of urinary sodium assessment in acute heart failure – European Heart Journal: Acute Cardiovascular Care

 


Case study: Urinary magnesium in the evaluation of hypomagnesemia

2 Nov, 2020 | 02:19h | UTC

Urinary Magnesium in the Evaluation of Hypomagnesemia – JAMA (free for a limited period)

 


KDIGO Controversies Conference on onco-nephrology

30 Oct, 2020 | 01:03h | UTC

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer – Kidney International

 

Commentary on Twitter

 


Randomized trial suggests rapid intermittent bolus of hypertonic saline is the best approach for the treatment of symptomatic hyponatremia

27 Oct, 2020 | 09:36h | UTC

Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial – JAMA Internal Medicine

 

 


[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes

25 Oct, 2020 | 23:34h | UTC

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Finerenone Linked to Reduced Cardiorenal Events for Chronic Kidney Disease – HCPLive

 

Commentary on Twitter (thread – click for more)

 


Randomized trial: Effects of regional citrate anticoagulation vs. systemic heparin anticoagulation on dialysis filter life span and mortality among critically ill patients with acute kidney injury

25 Oct, 2020 | 23:32h | UTC

Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial – JAMA (free for a limited period)

 

Commentary on Twitter

 


KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease

20 Oct, 2020 | 01:33h | UTC

KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease – Kidney International

Executive summary: 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment – Kidney International

 

Commentary on Twitter

 


[Abstract Only] Systematic review and meta-analysis of native kidney biopsy complications

20 Oct, 2020 | 01:26h | UTC

Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


[Abstract Only] Meta-analysis: Effect of urate-lowering therapy on cardiovascular and kidney outcomes

20 Oct, 2020 | 01:22h | UTC

Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial

15 Oct, 2020 | 09:00h | UTC

Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice – JAMA Internal Medicine

Commentaries: A Tale of 2 Blood Pressures – JAMA Internal Medicine AND Real-World BP Measurements vs SPRINT Protocol – Physician’s Weekly

 

Commentary on Twitter

 


COVID-19 and the kidney

8 Oct, 2020 | 09:02h | UTC

COVID-19 and the kidney – Cleveland Clinic Journal of Medicine

 


KDOQI clinical practice guideline for nutrition in CKD: 2020 update

6 Oct, 2020 | 00:08h | UTC

KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update – American Journal of Kidney Diseases

 


AHA Scientific Statement: Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease

29 Sep, 2020 | 10:00h | UTC

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association – Circulation

News Release: Newer Type 2 diabetes medications have heart and kidney disease benefits, too – AHA Newsroom

 


Randomized trial: Dapagliflozin in patients with chronic kidney disease

25 Sep, 2020 | 02:34h | UTC

Dapagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (free for a limited period)

Commentary: Dapagliflozin Cuts Renal Risks in Patients with CKD, Regardless of Diabetes Status – NEJM Journal Watch

 


JAMA Network Series: Medical Specialties and the COVID-19 Pandemic

24 Sep, 2020 | 09:45h | UTC

Editorial: The COVID-19 Pandemic and the JAMA Network

See articles:

 


[Abstract Only] Two-year, randomized, controlled trial of belimumab in lupus nephritis

17 Sep, 2020 | 09:20h | UTC

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis – New England Journal of Medicine (link to abstract – $ for full-text)

 


Multisystem effects of COVID-19: A concise review for practitioners

16 Sep, 2020 | 09:14h | UTC

Multisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine

 


State of the art review: Hepatorenal syndrome

15 Sep, 2020 | 08:41h | UTC

Hepatorenal syndrome: pathophysiology, diagnosis, and management – The BMJ (free for a limited period)

 

Commentary on Twitter

 


Acute kidney injury in hospitalized patients with and without COVID-19: A comparison study

11 Sep, 2020 | 01:44h | UTC

AKI in Hospitalized Patients with and without COVID-19: A Comparison Study – Journal of the American Society of Nephrology

Commentary: Deaths Sky High in Hospitalized COVID Patients With Kidney Injury – Medscape AND Acute Kidney Injury in COVID-19 Patients – Physician’s Weekly

 

Commentary on Twitter

 


[Abstract Only] Randomized trial: Antibiotics vs. no therapy in kidney transplant recipients with asymptomatic bacteriuria

11 Sep, 2020 | 01:10h | UTC

Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomised controlled trial – Clinical Microbiology and Infection

 

Commentary on Twitter

 


Podcast: Hyponatremia deconstructed

8 Sep, 2020 | 01:01h | UTC

REBOOT #48 Hyponatremia Deconstructed – The Curbsiders Internal Medicine Podcast

 


[Abstract Only] Randomized trial: Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas

20 Aug, 2020 | 09:13h | UTC

Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas – New England Journal of Medicine

 


Stay Updated in Your Specialty

 

No spam, just news.